Across TCGA pan-cancer cohorts, PRG3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRG3 data layer compared with 10 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRG3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRG3 expression acts as an unfavorable survival marker.
HNSC and UCEC are the cancer types where PRG3 Mutation most reproducibly stratifies survival.